A
AKTS
AKTIS ONCOLOGY INC
15.73
-1.03-6.15%After Hours: 15.80 +0.07 +0.45%19:59 10/23 EDT
OPEN/PREV CLOSE16.50/16.76
TODAY RANGE15.65-16.61
VOL241.76K
MARKET CAP845.44M
52 WEEK RANGE14.72-34.19
AVG VOL (3M)366.71K
% TURNOVER0.36%
TURNOVER--
P/E (TTM)-14.1419
% RANGE5.72%
EPS(TTM)-1.1123
P/E(FORWARD)-8.9922
P/B1.795
BVPS8.76
DIVIDEND--
P/S122.60
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP726.62M
SHARES OUTSTANDING53.75M
NEXT EARNINGS--
FREE FLOAT46.19M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·10/14 20:27
Aktis Oncology: Padcev Is Building The Market It Wants
TipRanks·10/05 08:05
Wedbush Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS)
Dow Jones·10/02 15:00
Aktis Oncology Price Target Maintained With a $35.00/Share by Wedbush
Benzinga·10/02 14:50
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target
Dow Jones·09/09 14:46
Aktis Oncology Price Target Announced at $40.00/Share by Oppenheimer
TipRanks·09/09 10:10
Aktis Oncology initiated with an Outperform at Oppenheimer
Dow Jones·08/19 12:52
Aktis Oncology Price Target Announced at $35.00/Share by Wedbush
TipRanks·08/19 11:05
Wedbush starts Aktis Oncology at Outperform on radiopharma potential
TipRanks·08/19 11:00
Aktis Oncology initiated with an Outperform at Wedbush
Dow Jones·08/19 10:21
Aktis Oncology Initiated at Outperform by BMO Capital
TipRanks·08/18 20:30
BMO starts Aktis at Outperform, says opportunities not captured in valuation
TipRanks·08/18 20:25
Aktis Oncology initiated with an Outperform at BMO Capital
Same Industry
Name/Symbol
Change%
Price